The US has voiced concerns over India's high customs duties on IP-intensive products and its proposed mandatory blanket license for AI developers using copyrighted works. India remains on the US's 'Priority Watch List' for inadequate IP protection, with specific worries about trade secret disclosure and patent revocations, particularly in the pharmaceutical sector.